Pharsight

Bristol Myers Squibb patents expiration

1. Eliquis patents expiration

ELIQUIS's oppositions filed in EPO
ELIQUIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6967208 BRISTOL MYERS SQUIBB Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Nov, 2026

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations
Feb, 2031

(7 years from now)

Drugs and Companies using APIXABAN ingredient

Market Authorisation Date: 28 December, 2012

Treatment: Prophylaxis of deep vein thrombosis and pulmonary embolism; Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Reduce the risk of recurrent deep vein thrombosis (...

Dosage: TABLET;ORAL

How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage

ELIQUIS family patents

Family Patents

2. Sprycel patents expiration

SPRYCEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491725 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Mar, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680103 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Feb, 2025

(1 year, 4 months from now)

US8680103

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Aug, 2025

(1 year, 10 months from now)

US7491725

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Sep, 2026

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2025
Pediatric Exclusivity (PED) Jun 21, 2026

Drugs and Companies using DASATINIB ingredient

Market Authorisation Date: 28 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage

SPRYCEL family patents

Family Patents

3. Zerit Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7135465 BRISTOL MYERS SQUIBB Sustained release beadlets containing stavudine
Feb, 2023

(7 months ago)

US7135465

(Pediatric)

BRISTOL MYERS SQUIBB Sustained release beadlets containing stavudine
Aug, 2023

(a month ago)

Drugs and Companies using STAVUDINE ingredient

Market Authorisation Date: 31 December, 2002

Treatment: Method for treating hiv-1 infection

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

ZERIT XR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic